Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
about
The insulin-like growth factor system in cancerNonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitorsThe Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated ProteinsTNF-insulin crosstalk at the transcription factor GATA6 is revealed by a model that links signaling and transcriptomic data tensors.Insulin receptor substrates (IRSs) and breast tumorigenesis.Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expressionNuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer.Defining the pathway to insulin-like growth factor system targeting in cancer.Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibitionMetformin and erlotinib synergize to inhibit basal breast cancer.OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.Therapeutic destruction of insulin receptor substrates for cancer treatment.Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.IRS and TOR nutrient-signaling pathways act via juvenile hormone to influence honey bee caste fate.Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modelingInsulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.BAG-1 interacts with the p50-p50 homodimeric NF-κB complex: implications for colorectal carcinogenesisTargeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line.Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity.Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?Impact of targeting insulin-like growth factor signaling in head and neck cancers.miR-448 suppresses proliferation and invasion by regulating IGF1R in colorectal cancer cells.Expression and function of the insulin receptor substrate proteins in cancerLack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancerCustomizing the targeting of IGF-1 receptor.Emerging drugs in the treatment of pancreatic cancer.Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.Minireview: Were the IGF Signaling Inhibitors All Bad?MiR200c targets IRS1 and suppresses prostate cancer cell growth.Study of the effects of cyclooxygenase-2 inhibitor on the promotion of hepatic tumorigenesis in rats fed a high fat diet.GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance.Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.MiR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells.MicroRNA-30a Inhibits Colorectal Cancer Metastasis Through Down-Regulation of Type I Insulin-Like Growth Factor Receptor.Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways.
P2860
Q27013945-2DBF4115-E75C-4E87-AAF6-347108DF371BQ27693185-AB83ED01-61CC-44EF-95EA-B839F094D8F8Q28088661-1261BB4B-BA0A-4CCE-AEFD-321429B557A5Q30276641-673B2611-9AC5-443E-95FA-448B7AE31D78Q33642166-85A0072B-9C0C-42F1-8FEB-843A98873AAAQ33813730-43E9FA35-68B5-43AE-A79A-0E0210E99B47Q33939890-748226E4-88B7-44CF-A254-865F34FB07D6Q34023117-DCA977F7-6ED4-4E54-848A-163A935FF337Q34107722-EE075C72-2692-4375-99D8-DA1F6DC9D3A8Q34187898-41679F3F-B784-40D8-AC88-9F26E298560DQ34786488-7252281A-683E-4737-BAC3-939BEF8CE0B3Q35131269-0381220E-F1D3-4510-B037-953373418FF7Q35343877-784D740C-63C8-4393-85DA-E02653CBD32CQ35494483-D963594B-05F3-4D86-9AC7-019E782909AAQ35539296-E298C58B-DD03-451E-BEC4-32FEEEDAC073Q35544606-116F6306-4FE9-40CF-960D-F76EA2089DB6Q35606589-7FDE6E59-9566-4DF3-87FF-F8720502BFCFQ35683561-20A80149-00A1-4DA3-9697-F5755A47B856Q35737918-F59E963C-7E76-4FC5-B2CC-1D542371A777Q35810171-98C91093-D470-4A20-BEA1-936B2D9C276FQ36230865-822C5CD0-230D-4B0B-8B9F-88A9C905FFEAQ36274510-6BD3A5E2-5903-40FB-AF22-4865DA1A70BBQ36357195-BE17A4F1-669E-4511-896F-0EE883429D8EQ37126107-9202FA48-A6FF-40B7-B1C0-3D7F2A460599Q37144049-CDD088BB-3BB8-4E58-A49A-831468AA5D06Q37257933-114A585F-3FE6-4204-893D-C0AB7AFF85E9Q37356570-0C9088D8-FCE9-4AB5-B81D-21E1AFBA35B4Q37401330-035CA094-1C4E-44B0-9B3D-5E7037BE2A33Q37494647-A7E547E2-9B9B-4558-96B7-ACD938AFFD65Q37657511-2472EC43-77C5-4B9D-9607-DD68EF9D1210Q38586367-7D3180CE-D963-4919-9E47-2A4AD5A5DAF8Q38909442-F35E6926-0DFC-4AD4-AAC5-AB9D90A09AA2Q40108804-F19D1ECD-036F-4E99-BA40-9DF33FB0645CQ42288454-98A0C69A-DD09-41E4-A92C-F6252EF28909Q43807392-400890DF-53FB-4ACD-B7BB-24DCF654D1BEQ44117797-E01AB260-968C-47AD-9AA1-BA6CF4F17196Q47769669-3E7434BF-BECD-4968-A01A-571273AB495DQ54610139-051FB31B-1B5C-4EC8-8C8C-6687ED437083Q55082954-1337A70D-5224-4BF3-930B-D2B13B22EAA6
P2860
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Insulin receptor substrate-1 i ...... ssa') response and resistance.
@en
type
label
Insulin receptor substrate-1 i ...... ssa') response and resistance.
@en
prefLabel
Insulin receptor substrate-1 i ...... ssa') response and resistance.
@en
P2093
P1476
Insulin receptor substrate-1 i ...... essa') response and resistance
@en
P2093
Denise Barrow
Helen E Jones
Iain R Hutcheson
Janice M Knowlden
Robert I Nicholson
P2888
P356
10.1007/S10549-007-9763-9
P407
P50
P577
2007-09-28T00:00:00Z
P6179
1037907096